Table 2.

Characteristics of limited study population (n = 27)

Characteristics of limited study population (n = 27)
Serum concentrations, n	27
Patients, n	27
Gender, n (%)
Male	26	(96.3)
Female	1	(3.7)
Age (years), n = 27, mean ± SD (min–max)	12 ± 3.4	(8–21)
Children ≤ 12 years, n (%)	14	(51.9)
Adolescents > 12 years, n (%)	13	(48.1)
Weight (kg), n = 27, mean ± SD (min–max)	49.5 ± 20.2	(21.9–85)
Nicotine abuse, n (%)	3	(11.1)
Oral contraception, n (%)	0	(0)
Dose (mg/day), n = 27, mean ± SD (min–max)	48.2 ± 19.4	(10–80)
Weight-normalized dose (mg/(kg x day)), n = 27, mean ± SD (min–max)	1.0 ± 0.3	(0.3–1.6)
Patients with ICD-10 diagnosis, n (%)	20
Attention deficit hyperactivity disorder, predominantly inattentive type (F90.0)	8	(40)
Attention deficit hyperactivity disorder, predominantly hyperactive type (F90.1)	10	(50)
Combined vocal and multiple motor tic disorder (F95.2)	2	(10)
Patients with comorbidities, n (%)	12
One comorbidity	10	(83.3)
More than one comorbidity	2	(16.7)
Comorbidities, n, multiple entries
Undifferentiated schizophrenia (F20.3)	1
Major depressive disorder, moderate (F32.1)	1
Anorexia nervosa (F50.0)	1
Sleep terrors (F51.4)	1
Specific reading disorder (F81.0)	3
Specific developmental disorder of motor function (F82.9)	1
Atypical autistic disorder (F84.1)	1
Other mixed disorders of conduct and emotions (F92.8)	2
Other childhood emotional disorders (F93.8)	2
Childhood emotional disorder, unspecified (F93.9)	1
Patients with comedication, n (%)	7
One comedication	6	(85.7)
More than one comedication	1	(14.3)
Comedication, n (%), multiple entries
Clozapine	1	(12.5)
Methylphenidate	2	(25)
Olanzapine	1	(12.5)
Pipamperone	1	(12.5)
Risperidone	2	(25)
Sodium valproate	1	(12.5)

SD standard deviation, min minimum, max maximum, ICD-10 International statistical classification of diseases and related health problems